Results 71 to 80 of about 5,542 (243)

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

BIOSIMILARS IN RHEUMATOLOGY

Научно-практическая ревматология, 2017
One of the most striking achievements in the pharmacotherapy of rheumatoid arthritis (RA) and other human immunoinflammatory diseases (IIDs) late in the 20th century is associated with the design of a fundamentally new group of medications that received ...
E. L. Nasonov
doaj   +1 more source

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, EarlyView.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia

Pragmatic and Observational Research, 2023
Giacomo M Bruno,1,2 Maria Chiara Valentino,2 Alessandra Brunetti,3 Sergio Di Matteo,2 Ivan Begovic,2 Edoardo Croce,4 Garifallia Sakellariou,5 Serena Bugatti,6 Pietro Perotti,7 Silvia Vecchio,7 Simona Migliazza,7 Roberto Langella,8 Giorgio L Colombo1,2 ...
Bruno GM, Valentino MC, Brunetti A, Di Matteo S, Begovic I, Croce E, Sakellariou G, Bugatti S, Perotti P, Vecchio S, Migliazza S, Langella R, Colombo GL   +12 more
doaj  

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. [PDF]

, 2016
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial ...
Arnold, Dirk, Cardoso, Fatima, Casali, Paolo G., Cervantes, Andrés, Ciardiello, Fortunato, Douillard, Jean-Yves, Eggermont, Alexander M. M., Eniu, Alexandru, Giuliani, Rosa, Jassem, Jacek, McGregor, Keith, Pentheroudakis, George, Peters, Solange, Rauh, Stefan, Stahel, Rolf A., Tabernero, Josep, Universitat Autònoma de Barcelona, Voest, Emile, Vyas, Malvika, Zielinski, Christoph C.   +19 more
core   +5 more sources

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, EarlyView.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]

, 2014
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R, Ambrósio, C, André, R, Araújo, F, Barcelos, F, Bernardes, M, Bogas, M, Canhão, H, Castelão, W, Coelho, PC, Cordeiro, I, Costa, L, Cunha, I, Duarte, C, Faustino, A, Fernandes, S, Fonseca, JE, Garcês, S, Gonçalves, J, Las, V, Leitão, R, Malcata, A, Maurício, L, Meirinhos, T, Melo-Gomes, JA, Miguel, C, Miranda, LC, Monteiro, P, Neto, A, Pereira da Silva, JA, Pimenta, S, Pimentel-Santos, FM, Pimentão, JB, Ramiro, Sofia, Ramos, JC, Roxo, Ana, Santos, H, Sepriano, A, Silva, C, Silva, M, Tavares, V, Teixeira, F   +41 more
core  

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars

Advances in Pharmacological and Pharmaceutical Sciences
Adalimumab, marketed as Humira, is a fully humanized monoclonal antibody that blocks the activity of tumor necrosis factor-alpha and is used in treating several autoimmune disorders. As one of the top-grossing pharmaceuticals, its global sales surpassed $
Ramya Nair, Naveen Krishnan, Vasudev Shenoy, Raviraja N. Seetharam   +3 more
doaj   +1 more source

Long range planning of biologics process development and clinical trial material supply process [PDF]

, 2011
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Engineering Systems Division; in conjunction with the Leaders for Global Operations Program at MIT, 2011.Cataloged ...
Edwards, Emily (Emily Rose)
core